The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1488
ISSUE1488
February 15, 2016
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Selexipag (Uptravi) for Pulmonary Arterial Hypertension
February 15, 2016 (Issue: 1488)
The FDA has approved selexipag (Uptravi – Actelion),
an oral selective prostacyclin IP receptor agonist, for
treatment of pulmonary arterial hypertension (PAH).
Treprostinil (Orenitram), an oral prostacyclin analog,
was approved earlier for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.